> ## Content Index
> Fetch the complete content index at: https://www.elenapintea.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Deviations, CAPAs and change control: a practical primer
- URL: https://www.elenapintea.com/deviations-capas-and-change-control-a-practical-primer/
- Published: 2026-10-14T18:03:30.000Z
- Updated: 2026-11-19T16:24:20.000Z
- Description: This primer explains each process in practical terms, with parallels from pharmacy practice, where the same logic applies on a smaller scale.
- Author: Elena Pintea
- Tags: GxP Documentation

Every pharmaceutical quality system rests on a few core processes (International Council for Harmonisation \[ICH\], 2008). Three of them, deviation management, corrective and preventive action (CAPA), and change control, determine how an organisation reacts when something goes wrong and how it changes things safely.

This primer explains each process in practical terms, with parallels from pharmacy practice, where the same logic applies on a smaller scale.

### Deviations: when reality differs from the plan

A deviation is any departure from an approved procedure, specification or standard. It might be a temperature excursion in a storage area, a missed step in a batch record or an out-of-specification test result.

A robust deviation process follows clear steps:

1. **Detect and contain.** Stop or isolate what is affected, such as quarantining a batch.
2. **Document immediately.** Record what happened, when, where and who was involved.
3. **Classify.** Assess whether the deviation is minor, major or critical, based on its potential impact on product quality and patient safety (ICH, 2023).
4. **Investigate.** Find the root cause, not just the immediate cause (U.S. Food and Drug Administration \[FDA\], 2006).
5. **Assess impact.** Decide whether the affected product can be released, needs rework or must be rejected.
6. **Define actions.** Link the deviation to CAPAs where needed.
7. **Close.** Approve the conclusion once actions are defined and the documentation is complete.

In pharmacy, a refrigerator that warms above 8 °C overnight is a deviation in the same sense. The products are quarantined, the duration and temperature are documented, stability information is checked, and a decision is made on whether they can still be used.

### CAPA: fixing problems so they don't come back

CAPA separates three different responses:

- **Correction:** fixing the immediate problem, for example re-labelling one mislabelled package.
- **Corrective action:** removing the root cause so the same problem does not recur, for example changing the labelling procedure.
- **Preventive action:** removing the cause of a *potential* problem before it happens, for example applying the improved procedure to similar product lines.

The step that is most often neglected is the **effectiveness check**. After a defined period, the organisation verifies whether the CAPA actually worked. If the same type of deviation keeps recurring, the root cause was probably not found (ICH, 2008).

A common weakness is a CAPA that only says "retrain staff". Training helps, but if the procedure, layout or system makes errors easy, retraining alone rarely solves the problem (National Patient Safety Foundation \[NPSF\], 2015).

### Change control: changing things without creating new risks

Change control manages planned changes to processes, equipment, materials, suppliers, documents or systems. Its purpose is to make sure every change is assessed before it is implemented (ICH, 2008).

A typical change control covers:

- **Description and justification:** what will change and why.
- **Impact assessment:** effects on product quality, validation status, regulatory filings, documentation, training and supply.
- **Approval:** by quality assurance and other affected functions.
- **Implementation plan:** tasks, owners and timelines.
- **Verification:** confirmation that the change was implemented as planned and achieved its aim.

Change control is also where quality assurance and regulatory affairs meet. If a change affects the marketing authorisation, a regulatory variation must be submitted and, for major changes, approved before implementation (Medicinal Products Ordinance \[VAM\], 2018).

### Complaints and recalls

Complaints and recalls are closely linked to these processes. A product complaint may reveal a quality defect, which triggers a deviation investigation and possibly a CAPA.

If a defect could put patients at risk, a recall may be needed. In Switzerland, quality defects must be reported to Swissmedic (Therapeutic Products Act \[TPA\], 2000, Art. 59), and recalls are classified by urgency and by how far down the supply chain they reach: wholesalers, pharmacies and hospitals, or patients.

On the pharmacy side, I have handled recall notices as part of inventory management: identifying affected batches, removing them from stock, documenting the action and, where needed, contacting patients.

### Documentation ties it all together

Each of these processes generates records that must meet ALCOA+ principles and be controlled in a document management system. Procedures and work instructions must be kept current, and staff must be trained on each new version before it takes effect (European Commission, 2011).

Auditors and inspectors frequently review deviation and CAPA records first. They show how well an organisation understands and controls its own processes.

### My experience with these principles

In my pharmacy roles I have supported regulatory compliance across prescription management, product storage and operations, and helped the lead pharmacist maintain quality and safety standards. In hospital practice, I worked in regulated clinical environments where documentation accuracy was essential.

My MSc training, GCP certification and continuing education in pharmaceutical legislation and good practice added the formal framework behind these daily habits.

### Why this matters to employers

Quality teams need people who can investigate calmly, write clear records, think in root causes rather than symptoms, and work across functions. These skills transfer directly from regulated pharmacy and hospital practice into pharmaceutical quality management.

### Key takeaways

- Deviations are documented, classified, investigated and assessed for impact before closure.
- CAPAs must address root causes and be checked for effectiveness.
- Change control assesses every planned change before implementation and links quality to regulatory affairs.

### References

European Commission. (2011). *EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use – Chapter 4: Documentation*. https://health.ec.europa.eu

International Council for Harmonisation. (2008). *Pharmaceutical quality system Q10*. https://www.ich.org

International Council for Harmonisation. (2023). *Quality risk management Q9(R1)*. https://www.ich.org

Medicinal Products Ordinance \[VAM\] of 21 September 2018, SR 812.212.21 (Switzerland). https://www.fedlex.admin.ch

National Patient Safety Foundation. (2015). *RCA2: Improving root cause analyses and actions to prevent harm*. National Patient Safety Foundation.

Therapeutic Products Act \[TPA\] of 15 December 2000, SR 812.21 (Switzerland). https://www.fedlex.admin.ch

U.S. Food and Drug Administration. (2006). *Quality systems approach to pharmaceutical CGMP regulations: Guidance for industry*. https://www.fda.gov